CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: However, when looking at the subset level, we found a significantly decreased level of HLA-DR+CD8+TCM in DN-CML (36.75% vs 12.40%, P = 0.0462) and a further decrease in TKI-F (36.75% vs 6.71%, P = 0.0087) and MR (37.75% vs 5.20%, P = 0.0082) patients compared to the control group.